BeiGene files patent suits against Sandoz and MSN to block generic BRUKINSA until 2034

BeOne Medicines Ltd.

Filed Hatch-Waxman infringement suits in District of New Jersey after Sandoz and MSN filed ANDAs with Paragraph IV certifications.
Composition of matter patent for BRUKINSA not challenged; remains intact and expires in 2034.
Complaints seek permanent injunction to prevent generic commercialization before expiration of asserted Orange Book patents.
ANDA litigation common in pharma; additional notices from other generic companies may follow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.